Literature DB >> 20556386

Unenhanced and contrast-enhanced ultrasonography during hepatic transarterial embolization and chemoembolization with drug-eluting beads.

Hippocrates Moschouris1, Katerina Malagari, Ioannis Kornezos, Marina Georgiou Papadaki, Panagiotis Gkoutzios, Dimitrios Matsaidonis.   

Abstract

The purpose of this study was to describe and evaluate the findings of unenhanced ultrasonography (US) and contrast-enhanced ultrasonography (CEUS) when these modalities are applied during transarterial embolization (TAE) or transarterial chemoembolization (TACE) of liver tumors. Sixteen tumors (9 hepatocellular carcinomas, 5 metastases from colorectal cancer, and 2 hemangiomas) were treated with TAE with microspheres and/or TACE with drug-eluting beads. All of these lesions were studied with intraprocedural unenhanced US and 12 were studied with intraprocedural CEUS. For the latter, a second-generation echo-enhancer (SonoVue; Bracco, Milan, Italy) and a low mechanical index technique were used. Intraprocedural findings were classified according to an arbitrary scale and were compared with pretreatment imaging (CEUS and computed tomography or CEUS and magnetic resonance imaging), with postembolization angiography, and with follow-up results. On unenhanced intraprocedural US, 13 of 16 tumors demonstrated intralesional high-level echoes of varying extent. These feature correlated poorly (r = 0.33, p = 0.097) with and generally underestimated the actual extent of necrosis. Exceptionally, high-level echoes that occupied the largest part of the treated lesions were associated with >50% tumor necrosis. Intraprocedural CEUS clearly depicted immediate partial or complete disappearance of tumor enhancement as a result of TAE/TACE. Three of 6 tumors with complete devascularization on postembolization angiogram showed residual enhancement on intraprocedural CEUS. Intraprocedural CEUS findings correlated closely (r = 0.91, p = 0.002) with follow-up findings. Intraprocedural sonography, particularly with echo-enhancers, could be used for intraprocedural monitoring in selected cases of liver tumors that undergo TAE or TACE.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20556386     DOI: 10.1007/s00270-010-9918-7

Source DB:  PubMed          Journal:  Cardiovasc Intervent Radiol        ISSN: 0174-1551            Impact factor:   2.740


  5 in total

1.  [Contrast-enhanced sonography. Therapy control of radiofrequency ablation and transarterial chemoembolization of hepatocellular carcinoma].

Authors:  E M Jung; W Uller; C Stroszczynski; D-A Clevert
Journal:  Radiologe       Date:  2011-06       Impact factor: 0.635

2.  The value of contrast-enhanced ultrasonography in detection of prostatic infarction after prostatic artery embolization for the treatment of symptomatic benign prostatic hyperplasia.

Authors:  Hippocrates Moschouris; Konstantinos Stamatiou; Katerina Malagari; Kyriaki Marmaridou; Konstantinos Kladis-Kalentzis; Michail Kiltenis; Nikolaos Papadogeorgopoulos; Aikaterini Tsavari; Kassiani Manoloudaki
Journal:  Diagn Interv Radiol       Date:  2019-03       Impact factor: 2.630

3.  Contrast-enhanced ultrasound after devascularisation of neuroendocrine liver metastases: functional and morphological evaluation.

Authors:  Aymeric Guibal; Thibaud Lefort; Laurence Chardon; Noura Benslama; Sébastien Mulé; Franck Pilleul; Catherine Lombard-Bohas; Lori Bridal; Jean Alain Chayvialle; Olivier Lucidarme; Alban Denys; Thomas Walter
Journal:  Eur Radiol       Date:  2012-09-22       Impact factor: 5.315

4.  Color coded perfusion imaging with contrast enhanced ultrasound (CEUS) for post-interventional success control following trans-arterial chemoembolization (TACE) of hepatocellular carcinoma.

Authors:  Janine Rennert; Isabel Wiesinger; Andreas Schicho; Lukas Philip Beyer; Philipp Wiggermann; Christian Stroszczynski; Ernst Michael Jung
Journal:  PLoS One       Date:  2019-06-10       Impact factor: 3.240

Review 5.  Contrast-Enhanced Ultrasound for Monitoring Treatment Response in Different Stages of Hepatocellular Carcinoma.

Authors:  Mariella Faccia; Matteo Garcovich; Maria Elena Ainora; Laura Riccardi; Maurizio Pompili; Antonio Gasbarrini; Maria Assunta Zocco
Journal:  Cancers (Basel)       Date:  2022-01-18       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.